拓扑替康作为二线药物治疗上皮性卵巢癌的临床研究.pdfVIP

现代妇产科进展 2001 年 9 月第 10 卷第 5 期 　Prog Obstet Gynecol ,Sept. 2001 ,Vol. 10 ,No. 5 ·论著· 拓扑替康作为二线药物治疗上皮性卵巢癌 的临床研究 黎 　莉 ,张 　昕 ,扈东艳 ( 山东大学齐鲁医院肿瘤中心化疗科 ,济南 　250012) 【摘要】　目的:探讨拓扑替康作为二线药物治疗卵巢上皮癌的疗效及安全性。方法 :经 ( 2 ) 病理证实的卵巢上皮癌 40 例 ,均可评价疗效和毒副作用。静脉滴注拓扑替康 1. 2mgm ·d 30min ,每日 1 次 ,连用 5d ,21d 为 1 周期 ,2 周期评价疗效。结果 :完全缓解率为 5. 0 % ,部分 缓解率为 17. 5 % ,总有效率为 22. 5 % 。主要毒副作用为骨髓抑制 ,非血液学毒性轻微 ,均 可耐受。结论 :拓扑替康是治疗卵巢上皮癌的有效的二线药物。 【关键词】　拓扑替康 ;卵巢肿瘤 ;治疗结果 ( ) 中图分类号:R737. 21 　文献标识码 :A 　文章编号 :1004 - 7379 2001 05 - 0353 - 03 Clinical study of topotecan as secondline agent for the treatment of epithelial ovarian carci noma. L i L i , Zhang X in , Hu Dongy an . The Cancer Center of Qilu Hosp ital , S handong University ,J inan 250012 　　【Abstract 】Objective : To evaluate the efficacy and safety profile of topotecan as secondline single agent chemotherapy in epithelial ovarian carcinoma. Methods :Forty patients with pathologi cally and cytologically confirmed epithelial ovarian carcinoma were studied. All 40 cases were evalu ated for both efficacy and safety. Topotecan was given as a 30min intravenous infusion at the dose of ( 2 ) 1. 2mgm ·d for 5 days and 21 days as a course. Efficacy was evaluated after 2 courses. Results : ( ) ( ) ( ) ( ) Complete remission CR rate was 5 % 240 ,partial remission PR rate was 17. 5 % 740 and a ( ) total effective rate was 22. 5 % 940 . Marrow suppression was the dominate side effect. Nonhema tological side effects were slight and tolerable. Conclusion : Topotecan appears as an e